# Signals Article: Putative Target Q15797 for Pulmonary Arterial Hypertension
Background
Pulmonary arterial hypertension (PAH) is a progressive cardiovascular disorder characterized by high blood pressure in the pulmonary arteries, leading to right heart failure and significant morbidity and mortality. Despite advances in treatment, PAH remains a challenging condition with limited therapeutic options. Identifying novel molecular targets could pave the way for new treatment strategies and improve patient outcomes.
Data-mining rationale
In a recent reanalysis effort, UniProt entry Q15797 was identified as a putative target for PAH. This candidate emerged from cross-referencing UniProt's reviewed human entries with expression-profiling studies in the NCBI GEO database, specifically datasets GDS:200313234, GDS:200278737, GDS:200287019, GDS:200250522, and GDS:200256539. Although Q15797 is present in these studies, it has not been associated with any registered Phase 1 or higher clinical programs, suggesting its potential as an unexplored target.
Why prior analyses may have missed this
Many of the GEO datasets containing Q15797 predate modern empirical-Bayes statistical methods, such as limma, which are crucial for accurate differential expression analysis. The absence of proper multiple-testing correction in earlier analyses may have led to the underestimation of Q15797's potential as a target for PAH. Additionally, the lack of integration with pathway and tissue-specific databases may have obscured its relevance.
Reasoning for further validation
To fully assess the potential of Q15797 as a target for PAH, several steps are recommended. Re-analyzing the matched GEO datasets using limma with Benjamini-Hochberg FDR correction will provide a more accurate picture of differential expression. Validation of top differentially-expressed genes by qPCR in an independent cohort is essential to confirm findings. Checking tissue specificity in GTEx and the Human Protein Atlas will help determine the target's relevance in the context of PAH. Running pathway analyses using STRING or OmniPath will provide insights into the biological context of Q15797. If validated, assessing the druggability of Q15797 via DGIdb and ChEMBL will be crucial for potential therapeutic development.